Districts (or national): Bronx

This study examined the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (funded by NIH) Report Links: Justman J. et al, 2018. Pharmacokinetics and pharmacodynamics of tenofovir reduced-glycerin 1% gel in the rectal and vaginal compartments in women: A cross-compartmental study with directly observed dosing. J Acquir Immune Defic Syndr. Web Links: https://clinicaltrials.gov/ct2/show/NCT01768962 https://mtnstopshiv.org/sites/default/files/attachments/MTN-014%20Version%202%200%201May2013_FINAL~CLEAN.pdf

This study investigated the experimental microbicide gel tenofovir to protect women against HIV. The study provided information on how much vaginal tenofovir gel, when used in combination with common vaginal products, will interfere with the local and or systemic exposure of the tenofovir, and vice versa, to optimize effectiveness as an HIV prevention tool. (funded by CONRAD) Schwartz, J., Justman, J., et al. 2016. In Vivo Drug-drug Interactions Between Tenofovir Gel and Three Commonly Used Vaginal Products. AIDS Research and Human Retroviruses, 32, 353-353. Web Links: https://clinicaltrials.gov/ct2/show/NCT01813162

HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP and demonstrated the superiority of cabotegravir for HIV prevention in these populations.

Closed to enrollment, in active study follow-up

Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094 https://www.hptn.org/research/studies/hptn083 https://giveprepashot.org/

HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The study enrolled and followed 2,700 men and transgender people who have sex with men in North America, South America, and Switzerland and demonstrated a reduced acquisition of HIV strains that were sensitive to the antibody. Web Links: https://www.hptn.org/research/studies/177 AMP Study Website https://clinicaltrials.gov/ct2/show/NCT02716675

HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for use in healthy, HIV-uninfected women. (funded by the NIH) Report Links: Seneviratne HK et al. 2020. Metabolism of Long-Acting Rilpivirine Following Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076). AIDS Res Hum Retroviruses. Bekker LG, et al. 2020. Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. EClinicalMedicine. Tolley EE, et. al. 2019. Acceptability of a long-acting injectable HIV prevention product among us and african women: Findings from a phase 2 clinical trial (HPTN 076). J Int AIDS Soc. Web Links: https://www.hptn.org/research/studies/152

A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and primary care

Soon to begin enrollment

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190

This randomized, double-blind, placebo-controlled multicenter s investigates the AstraZeneca (AZD1222) vaccine to prevent COVID-19

Closed to enrollment, follow up ongoing

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04516746

The SARS-COV-2 prevalence study is to assess the prevalence of active and recovered COVID infections in the Bronx community Open to enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04658121 https://www.compassstudy.org/

A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as preexposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1 infection Soon to begin enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04644029

A randomized, placebo-controlled efficacy trial of EVO100 vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhoeae infection in sexually active young women who have recently had Chlamydia or gonorrhea infection Soon to begin enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04553068

Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID). This multicenter study aims to rapidly identify safe and effective treatments for COVID-19. Ambulatory adults who have recently been diagnosed with mild to moderate COVID-19 may be eligible to receive one of several different treatments that are being studied concurrently in this double-blind, placebo-controlled trial.

Soon to begin enrollment

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04885530

The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month period. We will help you to download the app on your phone and provide you with HIV self-test kits and PrEP (if not already taking PrEP) in order to understand if the SmartPrEP app helps you remember to take your medication on schedule and increases your HIV self-testing patterns. You may also take part in interviews and focus groups as part of the study and we will be interested in having you provide your views on the features and usability of the app. The Making PrEP Smart study is active and is enrolling participants. Web Links: https://clinicaltrials.gov/ct2/show/NCT05111119 https://recruit.cumc.columbia.edu/studyinfopage/2254

This study examined the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (funded by NIH) Report Links: Justman J. et al, 2018. Pharmacokinetics and pharmacodynamics of tenofovir reduced-glycerin 1% gel in the rectal and vaginal compartments in women: A cross-compartmental study with directly observed dosing. J Acquir Immune Defic Syndr. Web Links: https://clinicaltrials.gov/ct2/show/NCT01768962 https://mtnstopshiv.org/sites/default/files/attachments/MTN-014%20Version%202%200%201May2013_FINAL~CLEAN.pdf

This study investigated the experimental microbicide gel tenofovir to protect women against HIV. The study provided information on how much vaginal tenofovir gel, when used in combination with common vaginal products, will interfere with the local and or systemic exposure of the tenofovir, and vice versa, to optimize effectiveness as an HIV prevention tool. (funded by CONRAD) Schwartz, J., Justman, J., et al. 2016. In Vivo Drug-drug Interactions Between Tenofovir Gel and Three Commonly Used Vaginal Products. AIDS Research and Human Retroviruses, 32, 353-353. Web Links: https://clinicaltrials.gov/ct2/show/NCT01813162

HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP and demonstrated the superiority of cabotegravir for HIV prevention in these populations.

Closed to enrollment, in active study follow-up

Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094 https://www.hptn.org/research/studies/hptn083 https://giveprepashot.org/

HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The study enrolled and followed 2,700 men and transgender people who have sex with men in North America, South America, and Switzerland and demonstrated a reduced acquisition of HIV strains that were sensitive to the antibody. Web Links: https://www.hptn.org/research/studies/177 AMP Study Website https://clinicaltrials.gov/ct2/show/NCT02716675

HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for use in healthy, HIV-uninfected women. (funded by the NIH) Report Links: Seneviratne HK et al. 2020. Metabolism of Long-Acting Rilpivirine Following Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076). AIDS Res Hum Retroviruses. Bekker LG, et al. 2020. Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. EClinicalMedicine. Tolley EE, et. al. 2019. Acceptability of a long-acting injectable HIV prevention product among us and african women: Findings from a phase 2 clinical trial (HPTN 076). J Int AIDS Soc. Web Links: https://www.hptn.org/research/studies/152

A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and primary care

Soon to begin enrollment

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190

This randomized, double-blind, placebo-controlled multicenter s investigates the AstraZeneca (AZD1222) vaccine to prevent COVID-19

Closed to enrollment, follow up ongoing

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04516746

The SARS-COV-2 prevalence study is to assess the prevalence of active and recovered COVID infections in the Bronx community Open to enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04658121 https://www.compassstudy.org/

A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as preexposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1 infection Soon to begin enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04644029

A randomized, placebo-controlled efficacy trial of EVO100 vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhoeae infection in sexually active young women who have recently had Chlamydia or gonorrhea infection Soon to begin enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04553068

Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID). This multicenter study aims to rapidly identify safe and effective treatments for COVID-19. Ambulatory adults who have recently been diagnosed with mild to moderate COVID-19 may be eligible to receive one of several different treatments that are being studied concurrently in this double-blind, placebo-controlled trial.

Soon to begin enrollment

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04885530

The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month period. We will help you to download the app on your phone and provide you with HIV self-test kits and PrEP (if not already taking PrEP) in order to understand if the SmartPrEP app helps you remember to take your medication on schedule and increases your HIV self-testing patterns. You may also take part in interviews and focus groups as part of the study and we will be interested in having you provide your views on the features and usability of the app. The Making PrEP Smart study is active and is enrolling participants. Web Links: https://clinicaltrials.gov/ct2/show/NCT05111119 https://recruit.cumc.columbia.edu/studyinfopage/2254

This study examined the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (funded by NIH) Report Links: Justman J. et al, 2018. Pharmacokinetics and pharmacodynamics of tenofovir reduced-glycerin 1% gel in the rectal and vaginal compartments in women: A cross-compartmental study with directly observed dosing. J Acquir Immune Defic Syndr. Web Links: https://clinicaltrials.gov/ct2/show/NCT01768962 https://mtnstopshiv.org/sites/default/files/attachments/MTN-014%20Version%202%200%201May2013_FINAL~CLEAN.pdf

This study investigated the experimental microbicide gel tenofovir to protect women against HIV. The study provided information on how much vaginal tenofovir gel, when used in combination with common vaginal products, will interfere with the local and or systemic exposure of the tenofovir, and vice versa, to optimize effectiveness as an HIV prevention tool. (funded by CONRAD) Schwartz, J., Justman, J., et al. 2016. In Vivo Drug-drug Interactions Between Tenofovir Gel and Three Commonly Used Vaginal Products. AIDS Research and Human Retroviruses, 32, 353-353. Web Links: https://clinicaltrials.gov/ct2/show/NCT01813162

HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP and demonstrated the superiority of cabotegravir for HIV prevention in these populations.

Closed to enrollment, in active study follow-up

Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094 https://www.hptn.org/research/studies/hptn083 https://giveprepashot.org/

HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The study enrolled and followed 2,700 men and transgender people who have sex with men in North America, South America, and Switzerland and demonstrated a reduced acquisition of HIV strains that were sensitive to the antibody. Web Links: https://www.hptn.org/research/studies/177 AMP Study Website https://clinicaltrials.gov/ct2/show/NCT02716675

HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for use in healthy, HIV-uninfected women. (funded by the NIH) Report Links: Seneviratne HK et al. 2020. Metabolism of Long-Acting Rilpivirine Following Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076). AIDS Res Hum Retroviruses. Bekker LG, et al. 2020. Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. EClinicalMedicine. Tolley EE, et. al. 2019. Acceptability of a long-acting injectable HIV prevention product among us and african women: Findings from a phase 2 clinical trial (HPTN 076). J Int AIDS Soc. Web Links: https://www.hptn.org/research/studies/152

A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and primary care

Soon to begin enrollment

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190

This randomized, double-blind, placebo-controlled multicenter s investigates the AstraZeneca (AZD1222) vaccine to prevent COVID-19

Closed to enrollment, follow up ongoing

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04516746

The SARS-COV-2 prevalence study is to assess the prevalence of active and recovered COVID infections in the Bronx community Open to enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04658121 https://www.compassstudy.org/

A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as preexposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1 infection Soon to begin enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04644029

A randomized, placebo-controlled efficacy trial of EVO100 vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhoeae infection in sexually active young women who have recently had Chlamydia or gonorrhea infection Soon to begin enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04553068

Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID). This multicenter study aims to rapidly identify safe and effective treatments for COVID-19. Ambulatory adults who have recently been diagnosed with mild to moderate COVID-19 may be eligible to receive one of several different treatments that are being studied concurrently in this double-blind, placebo-controlled trial.

Soon to begin enrollment

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04885530

The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month period. We will help you to download the app on your phone and provide you with HIV self-test kits and PrEP (if not already taking PrEP) in order to understand if the SmartPrEP app helps you remember to take your medication on schedule and increases your HIV self-testing patterns. You may also take part in interviews and focus groups as part of the study and we will be interested in having you provide your views on the features and usability of the app. The Making PrEP Smart study is active and is enrolling participants. Web Links: https://clinicaltrials.gov/ct2/show/NCT05111119 https://recruit.cumc.columbia.edu/studyinfopage/2254

This study examined the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (funded by NIH) Report Links: Justman J. et al, 2018. Pharmacokinetics and pharmacodynamics of tenofovir reduced-glycerin 1% gel in the rectal and vaginal compartments in women: A cross-compartmental study with directly observed dosing. J Acquir Immune Defic Syndr. Web Links: https://clinicaltrials.gov/ct2/show/NCT01768962 https://mtnstopshiv.org/sites/default/files/attachments/MTN-014%20Version%202%200%201May2013_FINAL~CLEAN.pdf

This study investigated the experimental microbicide gel tenofovir to protect women against HIV. The study provided information on how much vaginal tenofovir gel, when used in combination with common vaginal products, will interfere with the local and or systemic exposure of the tenofovir, and vice versa, to optimize effectiveness as an HIV prevention tool. (funded by CONRAD) Schwartz, J., Justman, J., et al. 2016. In Vivo Drug-drug Interactions Between Tenofovir Gel and Three Commonly Used Vaginal Products. AIDS Research and Human Retroviruses, 32, 353-353. Web Links: https://clinicaltrials.gov/ct2/show/NCT01813162

HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP and demonstrated the superiority of cabotegravir for HIV prevention in these populations.

Closed to enrollment, in active study follow-up

Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094 https://www.hptn.org/research/studies/hptn083 https://giveprepashot.org/

HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The study enrolled and followed 2,700 men and transgender people who have sex with men in North America, South America, and Switzerland and demonstrated a reduced acquisition of HIV strains that were sensitive to the antibody. Web Links: https://www.hptn.org/research/studies/177 AMP Study Website https://clinicaltrials.gov/ct2/show/NCT02716675

HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for use in healthy, HIV-uninfected women. (funded by the NIH) Report Links: Seneviratne HK et al. 2020. Metabolism of Long-Acting Rilpivirine Following Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076). AIDS Res Hum Retroviruses. Bekker LG, et al. 2020. Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. EClinicalMedicine. Tolley EE, et. al. 2019. Acceptability of a long-acting injectable HIV prevention product among us and african women: Findings from a phase 2 clinical trial (HPTN 076). J Int AIDS Soc. Web Links: https://www.hptn.org/research/studies/152

A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and primary care

Soon to begin enrollment

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190

This randomized, double-blind, placebo-controlled multicenter s investigates the AstraZeneca (AZD1222) vaccine to prevent COVID-19

Closed to enrollment, follow up ongoing

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04516746

The SARS-COV-2 prevalence study is to assess the prevalence of active and recovered COVID infections in the Bronx community Open to enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04658121 https://www.compassstudy.org/

A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as preexposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1 infection Soon to begin enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04644029

A randomized, placebo-controlled efficacy trial of EVO100 vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhoeae infection in sexually active young women who have recently had Chlamydia or gonorrhea infection Soon to begin enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04553068

Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID). This multicenter study aims to rapidly identify safe and effective treatments for COVID-19. Ambulatory adults who have recently been diagnosed with mild to moderate COVID-19 may be eligible to receive one of several different treatments that are being studied concurrently in this double-blind, placebo-controlled trial.

Soon to begin enrollment

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04885530

The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month period. We will help you to download the app on your phone and provide you with HIV self-test kits and PrEP (if not already taking PrEP) in order to understand if the SmartPrEP app helps you remember to take your medication on schedule and increases your HIV self-testing patterns. You may also take part in interviews and focus groups as part of the study and we will be interested in having you provide your views on the features and usability of the app. The Making PrEP Smart study is active and is enrolling participants. Web Links: https://clinicaltrials.gov/ct2/show/NCT05111119 https://recruit.cumc.columbia.edu/studyinfopage/2254

This study examined the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (funded by NIH) Report Links: Justman J. et al, 2018. Pharmacokinetics and pharmacodynamics of tenofovir reduced-glycerin 1% gel in the rectal and vaginal compartments in women: A cross-compartmental study with directly observed dosing. J Acquir Immune Defic Syndr. Web Links: https://clinicaltrials.gov/ct2/show/NCT01768962 https://mtnstopshiv.org/sites/default/files/attachments/MTN-014%20Version%202%200%201May2013_FINAL~CLEAN.pdf

This study investigated the experimental microbicide gel tenofovir to protect women against HIV. The study provided information on how much vaginal tenofovir gel, when used in combination with common vaginal products, will interfere with the local and or systemic exposure of the tenofovir, and vice versa, to optimize effectiveness as an HIV prevention tool. (funded by CONRAD) Schwartz, J., Justman, J., et al. 2016. In Vivo Drug-drug Interactions Between Tenofovir Gel and Three Commonly Used Vaginal Products. AIDS Research and Human Retroviruses, 32, 353-353. Web Links: https://clinicaltrials.gov/ct2/show/NCT01813162

HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP and demonstrated the superiority of cabotegravir for HIV prevention in these populations.

Closed to enrollment, in active study follow-up

Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094 https://www.hptn.org/research/studies/hptn083 https://giveprepashot.org/

HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The study enrolled and followed 2,700 men and transgender people who have sex with men in North America, South America, and Switzerland and demonstrated a reduced acquisition of HIV strains that were sensitive to the antibody. Web Links: https://www.hptn.org/research/studies/177 AMP Study Website https://clinicaltrials.gov/ct2/show/NCT02716675

HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for use in healthy, HIV-uninfected women. (funded by the NIH) Report Links: Seneviratne HK et al. 2020. Metabolism of Long-Acting Rilpivirine Following Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076). AIDS Res Hum Retroviruses. Bekker LG, et al. 2020. Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. EClinicalMedicine. Tolley EE, et. al. 2019. Acceptability of a long-acting injectable HIV prevention product among us and african women: Findings from a phase 2 clinical trial (HPTN 076). J Int AIDS Soc. Web Links: https://www.hptn.org/research/studies/152

A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and primary care

Soon to begin enrollment

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190

This randomized, double-blind, placebo-controlled multicenter s investigates the AstraZeneca (AZD1222) vaccine to prevent COVID-19

Closed to enrollment, follow up ongoing

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04516746

The SARS-COV-2 prevalence study is to assess the prevalence of active and recovered COVID infections in the Bronx community Open to enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04658121 https://www.compassstudy.org/

A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as preexposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1 infection Soon to begin enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04644029

A randomized, placebo-controlled efficacy trial of EVO100 vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhoeae infection in sexually active young women who have recently had Chlamydia or gonorrhea infection Soon to begin enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04553068

Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID). This multicenter study aims to rapidly identify safe and effective treatments for COVID-19. Ambulatory adults who have recently been diagnosed with mild to moderate COVID-19 may be eligible to receive one of several different treatments that are being studied concurrently in this double-blind, placebo-controlled trial.

Soon to begin enrollment

Web Links:
https://clinicaltrials.gov/ct2/show/NCT04885530

The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month period. We will help you to download the app on your phone and provide you with HIV self-test kits and PrEP (if not already taking PrEP) in order to understand if the SmartPrEP app helps you remember to take your medication on schedule and increases your HIV self-testing patterns. You may also take part in interviews and focus groups as part of the study and we will be interested in having you provide your views on the features and usability of the app. The Making PrEP Smart study is active and is enrolling participants. Web Links: https://clinicaltrials.gov/ct2/show/NCT05111119 https://recruit.cumc.columbia.edu/studyinfopage/2254